THE CANCER PROGRESS REPORT released by the American Association for Cancer Research argues that although funded research continues to spur progress against cancer, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for NIH, NCI, and FDA.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
